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the universe,” he says. He
believes philosophical
investigations are neither superior
to, or prior to, investigations in the
natural sciences. Concern about
free will is one of the key issues
behind most of the resistance to
materialism generally and neo-
Darwinism in particular, he says.
Dennett spells out just how the
process of natural selection can
generate organisms with greater
choice in their actions. “We are
now finding increasing complexity
throughout the developing
spectrum of organic life. The more
complex creatures become, the
wider is the range of activities
open to them. And with that
increase goes a steadily
increasing degree of freedom,” he
says. “The freedom of the bird to
fly wherever it wants is definitely a
kind of freedom, a distinct
improvement on the freedom of
jellyfish to float wherever it floats,
but a poor cousin of human
freedom.”
He sees Descartes’ split
between body and soul as one of
the key problems needing to be
confronted. People are still “made
anxious by the thought that if
science shows, as it were, that
there’s nobody home in a human
body, then there is nobody to
blame and there is nobody to take
pride,” he says. “So the task for
the naturalist like me is to show
how there can still be persons
without being Cartesian persons,
without there being a little
immaterial soul that animates and
controls the body like a
puppeteer. That is a hard thing to
show, but I think I can.”
“My main task – and it feels like
moving a mountain – is to get
people to realize that determinism
and inevitability are not
synonyms. There is no interesting
relationship between determinism
and inevitability. If your world is
determined, it doesn’t mean that
your future is inevitable,” he says.
The way to get at this is by taking
the word ‘inevitable’ and looking
at what it means, he believes. “It
means unavoidable. Its opposite
is avoidable or evitable. So, what
you have to show is that you have
an evolutionary process in a
deterministic universe, then what
you get is growth and the eventual
explosion of evitability.” As
complexity evolves, more and
more things become avoidable.
“What is ironic is that it is the very
predictability that science gives
you increases that evitability. It is
because we can foresee the
outcomes of various
circumstances that we can take
action to avoid them, and the
reason we are so much more free
than other organisms is because
we can see farther into the future
because we have more
knowledge.”
Free will is an evolved creation
of human activity and beliefs, and
it is just as real as such other
creations as music and money, he
says. It “does not require any
‘human exceptionalism’ that must
shake a defiant fist at Darwin.”
Determinism, he says, is not
fatalism. Fatalism teaches that
human effort makes no difference
to what happens, and we know
this is false. Human effort often
does make that difference.
“What makes this effectiveness
seem impossible is not science
but the rhetoric that has depicted
the mind as a separate, helpless
substance being pushed around
by matter,” says philosopher Mary
Midgely, who has welcomed the
new book. That simplification
grew from “the conviction that a
single simple pattern, found in the
interaction of its smallest particles
must govern the whole of nature,”
she says.
Dennett’s attempt to draw ‘free
will’ into the entirely materialist
and scientific view of the world
provides a boost and a challenge
to those still seeking to
understand the full evolutionary
legacy of Darwin’s work.
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Why this name? Little to do with
large Japanese wrestlers.... SUMO
stands for small ubiquitin-related
modifier. Although the SUMO
sequence is only 19% identical to
ubiquitin, its three-dimensional
structure is very similar. The
‘official’ name for SUMO-1 is
SMT3C; the related SUMO-2 and
SUMO-3 proteins are SMT3A and
SMT3B, respectively, in GenBank
and SwissProt. As usual,
researchers don’t care too much
about official names and generally
use SUMO, probably because it
goes so well with the term
‘wrestling’ (see literature).
Are there more than one?
Depends on the species. Budding
yeast, Caenorhabditis elegans and
Drosophila have just one gene for
SUMO, and this is essential in
yeast at least. Humans and mice
have three SUMO genes; however,
there are other ubiquitin-like
proteins that are not considered
SUMOs (although some of them
behave similarly).
What do they do? Like ubiquitin,
SUMO is covalently conjugated to
other proteins, in a similar
multistep process to ubiquitination.
SUMO is first processed to its
active form by removal of its last
four amino acids to leave two
essential glycine residues at the
carboxyl terminus. It is then
activated by formation of a
thioester between the carboxy-
terminal glycine and a cysteine of
the SUMO-activating E1 enzyme
(SAE1–SAE2), transferred to a
conjugating E2 enzyme (Ubc9) and
finally passed to the ε amino group
of specific lysine residues on target
proteins. In some cases, at least,
this last step is regulated by
SUMO-specific ligases (E3s).
What don’t they do? Unlike
ubiquitination, SUMOlation does
not target proteins for degradation.
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Plain speaking: Daniel Dennett has not
strayed from exploring the implications
of Darwin’s work and believes he now
has an evolutionary explanation for the
development of free will. 
It also differs in its narrow
substrate range and specificity: in
most cases the target is a lysine
within the consensus sequence
ΦKXE, where Φ is a hydrophobic
amino acid, K the modified lysine,
X any amino acid and E a
glutamate. SUMO also differs from
ubiquitin in usually not forming
poly-SUMO chains in vivo.
Do they all do the same?
Allegedly, no. SUMO-1 and SUMO-
2/3 show a difference in their
global target protein preferences.
RanGAP1, for instance, is
preferentially modified by SUMO-1,
and LEF1 preferentially by SUMO-
2. But many target proteins seem
able to accept any SUMO if it is
overproduced in the cell. We don’t
yet know in general whether it
makes a functional difference
which SUMO is attached to a
target molecule.
Does it stay or does it go?
SUMOlation is a highly dynamic
and fully reversible modification. A
family of cysteine proteases
specifically hydrolyze SUMO
isopeptide bonds. The yeast
enzymes, Ulp1 and Ulp2, are found
at the nuclear pore and in the
nucleoplasm, respectively.
Mammals have at least nine SUMO
proteases, known by various
names such as SuSP, SuPr or
SENP1–9. They are localized in
different subcellular
compartments, such as the PML
nuclear bodies (SENP1), the
cytoplasm (SENP6), the nucleolus
(SENP3) or at the nuclear pore
(SENP2). Interestingly, an isoform
of SENP2 called SuPr-1 also
localizes to PML nuclear bodies.
What cellular processes use
SUMO? Mitosis, for one thing. In
budding yeast, overexpression of
the SUMO SMT3 rescues a defect
in mitosis caused by mutation of a
centromere protein. And de-
SUMOlation of topoisomerase II
regulates mitotic cohesion of
sister-chromatid centomere in
budding yeast.
They also seem important in
the subnuclear structures known
as PML nuclear bodies, where
many SUMOlated proteins — such
as PML, Sp100, Daxx and p53 —
can be found. PML nuclear bodies
are large, insoluble nuclear
aggregates which contain many
functionally important proteins.
SUMOlation of PML is required for
the recruitment of some proteins
to PML nuclear bodies, such as
Daxx (though not PML itself).
There is some evidence that
SUMOlation is actively involved in
the nuclear import of substrates
containing a classical nuclear
localization signal; for example,
budding yeast with a conditional
defect in SUMO conjugation is
defective for nuclear import.
A number of transcription
factors are SUMOlated. Among
them are p53, the  androgen
receptor, LEF1, C/EBPs, Sp3 and
many more. SUMO modification
can either activate or, more
frequently, repress their
transactivating function. Several
transcriptional coregulators are
also SUMOlated: for example,
GRIP1 and several histone
deacetylases. The transcriptional
regulators of the PIAS family —
protein inhibitors of activated
STATs — were recently found to
be SUMO-specific ligases.
…And how do they really do it?
We just don’t know. SUMOlation
might act like a ‘big’
phosphorylation that changes the
conformation of proteins it
modifies and thereby alters the
function. Or it might serve as a
transferable protein–protein
interaction interface. Some
researchers argue that SUMO
competes with ubiquitin for
specific lysines in target proteins,
thereby balancing degradation
with stability. Combined with the
possibility that SUMO directs
proteins to particular cellular
locations, the real function of
SUMO is likely to involve all of the
above.
Which proteins are modified by
SUMO? A long and growing list:
Sp100; PML; RanGAP1; RanBP2;
IκBα; p53; p73; HIPK2; Daxx;
GRIP1; various HDACs; MITR; the
androgen, glucocorticoid and
progesterone receptors; the PIAS
family proteins; Ubc9;
Mdm2/Hdm2; Ap2; Axin; Sp3,
PCNA; septins; topoisomerases I
and II; Wrn; C/EBPs; GLUT4;
ARNT; CaMKII; SALL1; LEF1;
TIF1α; IRF1; HSF2; an increasing
number of viral proteins. In the end
we find ourselves asking, which
protein is not SUMO modified?
Beyond SUMOs: Covalent protein
modification by other proteins is
not limited to ubiquitin and
ubiquitin-related proteins. For
instance, Apg12 shows no obvious
similarity to ubiquitin but can
covalently modify target proteins
by a mechanism analogous to
ubiquitination. The same goes for
Hub1, which shows only very weak
similarity to ubiquitin: it even lacks
the canonical double glycine at the
processed carboxyl terminus, but
has a double tyrosine instead.
Covalent modification of proteins
by other proteins might therefore
be a more frequent phenomenon
than previously recognized. There
are probably many more modifying
proteins to be identified in the
future.
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